Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYP0035 plus Fulvestrant in PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer
NCT07784036Phase 3Not yet recruiting
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Sep 2026
- Primary completion
- Nov 2028
01
Overview
A Phase 3 trial of JYP0035 in breast cancer, sponsored by Guangzhou JOYO Pharma. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
JYP0035
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07784036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784036.